VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal?

Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced results from its Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease.

Viridian stated that the REVEAL-1 trial of Elegrobart met its primary endpoint of proptosis responder rate (PRR) with a highly statistically significant treatment effect in the four-week dosing regimen.

However, the company stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.

Retail sentiment on Stocktwits around Viridian Therapeutics trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.

Get updates to this developing story directly on Stocktwits.

Also See: ROMA Stock Shot Up 10% Today – Everything To Know About Its Gigantic Share Repurchase Program

For updates and corrections, email newsroom[at]stocktwits[dot]com.